-
-
-
-
-
-
About Genesis Therapeutics
Related fields
Categories
Related News
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry By Investing.com
Mirai's machine intelligence-based, open platform unlocks delivery to any tissue and cell type through rapid, iterative learning of in vivo tested chemistries Co-optimization of cargo design and manufacturing ensure the best possible medicine and manufacturing strategy for each new program Company emerges with an initial commitment of from Flagship Pioneering , /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled , a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. Mirai's machine intelligence-based, open platform uses proprietary data algorithms and machine intelligence to unlock delivery to any tissue and cell type, optimize cargo design, and facilitate manufacturing, accelerating genetic medicines toward successful clinical translation for the company's partners. Mirai plans to further advance its platform with Flagship's initial commitment of , aiming to enhance and accelerate genetic medicine development across a wide range of therapeutic areas and modalities. "We are in the age of information molecules, yet enormous technological challenges in the delivery, cargo design, and manufacturing of these molecules have hindered the speedy and full realization of their potential," said , Ph.D., Founding President of Mirai and Operating Partner at Flagship Pioneering. "We created Mirai to solve these key limitations through AI trained on high quantities of quality in vivo data. By applying machine intelligence to the design of every atom within the medicine and opening this platform to the entire industry, we will have vast collective data points rolling through our optimization loops, allowing a greater innovation advantage to benefit each partner on the Mirai platform." Mirai's cutting-edge platform is enabled by high throughput automation and in vivo multiplexing, generating vast amounts of data that fuel extensive optimization loops. The co-optimization of delivery, design, and manufacturing has the potential to enable a higher probability of success and a faster development timeline for any genetic medicine. , Executive Chair at Mirai and Growth Partner, Flagship Pioneering, added, "Every new company with a payload idea faces the same challenge of either internally building high-quality, cost intensive delivery, design, and manufacturing capabilities, or externally sourcing these components, which can be fragmented and suboptimal. Leveraging learnings from semiconductors as a centralized resource model that fueled the rapid advancement of tech, we've developed a solution that's been hiding in plain sight: an open platform to unlock genetic medicine development. Through aggressive investment in our own capabilities and expertise, and by creating long-term partnerships with biotech and pharma leaders in the space, Mirai's hope is to become the partner of choice and help bring more medicines into the world than we would ever achieve alone." , Ph.D., Founding CEO of Mirai and , Flagship Pioneering remarked, "Machine intelligence is transforming drug discovery and development as we know it, harnessing immense amounts of data to drive tomorrow's greatest innovations. The design space of genetic medicines is effectively infinite, and Mirai is pioneering the next big leap forward for us all." has built an open platform driven by machine intelligence that solves the key limitations hindering today's genetic medicines " delivery, design, and manufacturing. The company's platform combines the generative design of precise delivery solutions co-optimized with best-in-class manufacturing to develop the future of genetic medicine. Founded by Flagship Pioneering in 2021, Mirai is led by experts with decades of collective experience driving innovation in genetic medicines. About Flagship Pioneering Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than in aggregate value. To date, Flagship has deployed over in capital toward the founding and growth of its pioneering companies alongside more than of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including¯Foghorn Therapeutics¯(NASDAQ: FHTX),¯Moderna¯(NASDAQ: MRNA),¯Omega Therapeutics¯(NASDAQ: OMGA),¯Sana Biotechnology¯(NASDAQ: SANA),¯Generate Biomedicines,¯Inari,¯Indigo Agriculture, and¯Tessera Therapeutics.
Investing.com UK
Thu, 26 Sept, 12:18 PM UTC
Insilico Medicine's PandaOmics Box enhances drug discovery with advanced AI capabilities
InSilico MedicineJul 25 2024 The development of innovative medicines is an expensive, time-consuming and risky business. On average, it usually takes at least a decade and billions of dollars to bring a new drug from project initiation to approval. Identifying effective targets and conducting biological analysis is the first step in the process and remains a top priority in drug development. To facilitate for maximum data privacy and data security, Insilico Medicine ("Insilico"), developed a hardware platform, PandaOmics Box, that does not require Internet access and allows for on-premise biological analytics, target identification, biomarker discovery, indication prioritization and advanced research in personalized medicine and drug discovery. The PandaOmics Box is a seamless integration of Insilico's proprietary generative biology AI software PandaOmics, extensive scientific database, and advanced hardware system with state-of-the-art computational power and chip-level confidential computing. Designed for on-premise deployment, the PandaOmics Box allows the product to operate efficiently in a completely offline mode, therefore provides a secure environment for privacy data analysis. The solution is centered on PandaOmics, which encompasses more than 20 predictive models and generative biology models, and includes a full spectrum of transcriptomics, genomics, epigenomics, proteomics, single cell data and compound information generated by the scientific community. It supports professional target ranking, analysis and filters, empowering more efficient and convenient research for potential targets and biomarkers. It is further enhanced by a powerful local Large Language Model (LLM), marking it as a truly all-encompassing tool for research. Its array of additional superior features include: ChatPandaGPT, which allows researchers to engage with Insilico Medicine's knowledge graph database via intuitive, natural language conversations; Gene-Disease Report function, which streamlines the user's research efforts by automatically generating comprehensive reports that provide a comprehensive analysis of a specific research area, and Paper Drafting Tool, which is designed to assist researchers in creating well-structured draft papers, making the transition from research to publication smoother. Additionally, the system is equipped with OpenAPI framework, and allows Bioinformatics access to PandaOmics' extensive database and advanced AI algorithms. This feature provides researchers the flexibility to develop their own custom analyses, enabling them to create innovative methods that blend with their proprietary data for deeper insights. Personal medical and biological data must be secure and there is nothing more secure than a device that does not connect to the Internet, does not even have WiFi and even internally uses on-chip confidential computing but can perform many research functions that previously required access to the Internet or were not possible at all. While many hospitals, institutes, and biotech companies hold large amounts of data of their own, they are concerned that putting data in the cloud will lose its value or violate data privacy regulations. We want to help them unlock the value of that data, generate unprecedented value for the patients, and perform cutting-edge research. We offer on-premise PandaOmics Box that supports scientists to conduct cutting-edge tasks such as target identification, biomarker discovery, and indication prioritization in one hardware with no internet connection. Also, the array of exceptional features supported by LLM and open API further enhance the research experience." Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine Overall, PandaOmics Box, the innovative platform, is tailor-made to transform the research landscape, empowering researchers to excel in target identification, biomarker discovery and indication prioritization. Leveraging Insilico Medicine's exceptional AI capabilities, researchers are equipped with a powerful ally in their quest for groundbreaking advancements in target identification and drug development. Insilico Medicine is a pioneer in using generative AI for drug discovery and development. The Company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform, which includes generative biology, chemistry, and medicine. Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 promising therapeutic assets and has advanced seven molecules to the clinical stage. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug - a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI currently in Phase II trials with patients. InSilico Medicine
News-Medical.net
Fri, 26 Jul, 4:07 AM UTC
Metagenomi Showcases AI-Driven Advancements in Gene Editing at Cold Spring Harbor Laboratory Conference
Metagenomi, a genetic medicines company, presents its AI-enabled Smart Editing platform advancements at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference, highlighting progress in gene editing technology.
2 Sources
Fri, 30 Aug, 8:12 AM UTC
SOPHiA GENETICS : Unveils New Generation of the SOPHiA DDM™ Platform at Morgan Stanley Healthcare Conference 2024
Boston, MA and Rolle, Switzerland, September 4, 2024 - SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal analytics modules. As cancer cases continue to rise across the globe, our understanding of the disease becomes more nuanced. Newer, more effective therapies are being developed each day, and data is becoming increasingly critical in diagnosis, therapy selection, and drug development. Since launching the first generation of SOPHiA DDM™ in 2015, the Platform has been at the forefront of these innovations, accelerating the practice of data driven medicine globally as a leading platform in healthcare for using data to improve patient care. Data computed daily by the Platform has surged over the years with over 1.8 million genomic profiles being analyzed on the platform, at a rate of almost 30,000 analyses per month. As the volume and utility of data grows, SOPHiA GENETICS continues to accelerate innovation in the field of data-driven medicine by unveiling best-in-class technology and data science capabilities. The new generation SOPHiA DDM™ Platform offers a new, web-based architecture, which allows the Platform to compute and process data more efficiently by leveraging microservices as well as the newest technologies in cloud computing and GPUs from partners such as NVIDIA and Microsoft. Faster data processing not only optimizes computing, but it also provides answers more rapidly. Customers will experience faster turnaround time from data upload to insights. In addition, more efficient data processing capabilities enable the launch of new capabilities, such as the new whole genome sequencing (WGS) application being released later this year. It also enables new capabilities in multimodal analytics, which require processing of more complex and sizeable data sets across data modalities. Under the new generation of SOPHiA DDM™, genomic, radiomic, and multimodal analytics capabilities will be offered in a single, integrated workspace. Customers benefit from the three analytics modules by selecting applications that best suit their needs: "As our understanding of diseases becomes even more nuanced, we need to continue to grow and adapt our solutions to be able to field this complexity with speed and accuracy. Our customers are relying on us to provide them with innovative solutions that can accelerate their workflows," said Zhenyu Xu, Chief Scientific Officer, SOPHiA GENETICS. "Our decentralized, multimodal analytics platform supports customers and helps break data silos by creating a global community where knowledge is safely and securely shared amongst users. The new generation of our SOPHiA DDM™ Platform is revolutionizing the user experience by blending our powerful AI algorithms with multimodal data to produce meaningful insights to further the field of precision medicine." Abhimanyu Verma, Chief Technology Officer, SOPHiA GENETICS, added, "We pride ourselves on adapting our technology to meet our customers' needs. As the technology infrastructure at most healthcare organizations worldwide has evolved, we are thrilled to continue to provide best-in-class technology and set them up for success. This new generation of our platform will allow us the flexibility to respond quickly to our customer's evolving needs and introduce new features faster, and more efficiently." SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence SOPHiA GENETICS Forward-Looking Statements:
Market Screener
Wed, 4 Sept, 10:06 AM UTC
Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics
BELFAST, Northern Ireland, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonrai Analytics (Sonrai), an AI precision medicine company providing advanced analytics to advance therapeutic development, is working to bring its innovative cloud-based AI technology to the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital (MGH), enabling the Termeer Center to integrate and analyze its vast and complex data for more meaningful insights and faster analysis. The Termeer Center will utilize Sonrai's AI technology platform, Sonrai Discovery, with integrated bioinformatic pipelines to integrate and analyze its diverse data types, including multi-omics, and clinical data. Sonrai Discovery will act as the first point of access to the Termeer Center's data, allowing MGH researchers, bioinformaticians, and clinicians to collaborate seamlessly within one centralized environment. Sonrai Discovery will accelerate turnaround from raw data to analysis, maximizing research output and publishing of data. Sonrai's cloud-based platform will also ensure data security and compliance with data protection regulations to safeguard patient information. With Sonrai Discovery, the Termeer Center can maximize its research output in high-impact publications and enhance grant funding opportunities for oncological research. Sonrai's platform will also enable the Termeer Center to bridge the gap between its bioinformaticians and translational researchers, creating time efficiencies and collaborative efforts, while simultaneously creating a pathway for skill enrichment for postdocs and fellows. "We are committed to supporting innovation with our collaborators working on advancing the world of precision medicine and developing novel therapeutics to help patients beat cancer. The ability to integrate complex data such as multi-omics, allows researchers to gain new insights and generate results faster," said Prof. Darragh McArt, CEO and Founder, Sonrai Analytics. "We are proud to be supporting MGH and the Termeer Center to help drive innovation in the field of oncology and personalized biomarker-based cancer therapies." About Sonrai Sonrai Analytics is an AI precision medicine company. Sonrai's platform, Sonrai Discovery, accelerates drug development by enabling biotechnology and pharmaceutical partners to manage and analyze precision medicine data. By leveraging Sonrai Discovery, companies can better select promising compounds for clinical trials, maximizing trial success and patient outcomes. Sonrai's technology supports major life sciences and healthcare businesses across Europe and the US. More info: sonraianalytics.com. Sonrai Discovery is a cloud-based AI data management platform that enables biotech and pharma companies to manage and analyze their multi-modal datasets to accelerate precision medicine. Note: Image for illustrative purposes only and does not represent actual data from the Termeer Center or MGH. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/089a6e57-b77f-409a-a479-8f251b6ee062 Contact Details: Hanna Bielecka, h.bielecka@sonraianalytics.com Market News and Data brought to you by Benzinga APIs
Benzinga
Wed, 6 Nov, 4:39 PM UTC
Similar products
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 Triveous Technologies Private Limited
